Loading...
Loading...
ARQT| Name | Value |
|---|---|
| Revenues | 81.5M |
| Cost of Revenue | 7.5M |
| Gross Profit | 74.0M |
| Operating Expense | 88.6M |
| Operating I/L | -14.6M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.0M |
| Pretax | -15.5M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -15.9M |
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company specializing in developing and commercializing treatments for dermatological diseases. Its lead product candidate, ARQ-151, is a topical roflumilast cream that has completed Phase III clinical trials for plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation for seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 for alopecia areata treatment.
